Nyrada

IRM Restrict Access Settings


 
    Nyrada Commences Key Brain Injury Program Preclinical Study  
 
    Nyrada Commences Key Brain Injury Program Preclinical Study  
 
    Nyrada Commences Key Brain Injury Program Preclinical Study  
 
    Corporate Governance  
 
    Certificate of Incorporation  
 
    The Company By-Laws  
 
    Notice of Change of Interests of Substantial Securityholder  
 
    Notice of Change of Interests of Substantial Securityholder  
 
    Cleansing Statement  
 
    Application for quotation of securities - NYR  
 
    Amended and Restated Certificate of Incorporation and Bylaw  
 
    ‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 2  
 
    Change of Director's Interest Notice - CC  
 
    Change of Director's Interest Notice - MF  
 
    Change of Director's Interest Notice - RW  
 
    Change of Director's Interest Notice - JM  
 
    Notification of cessation of securities - NYR  
 
    4 of the best performing pharma & biotech stocks to begin the new year  
 
    Company Overview  
 
    4 of the Best Performing Pharma & Biotech Stocks to Begin the New Year  
 
    The next Neuren? Nyrada chases after two big markets  
 
    Nyrada Successfully Raises $1.755 Million via Placement  
 
    Proposed issue of securities - NYR  
 
    Proposed issue of securities - NYR  
 
    Nyrada Successfully Raises $1.755 Million via Placement  
 
    Trading Halt  
 
    This week’s Bulls N’ Bears top ASX runner is … Nyrada.  
 
    This week’s Bulls N’ Bears top ASX runner is … Nyrada.  
 
    Guess which ASX pharmaceuticals stock is up 400% in 2 days  
 
    Nyrada CEO exclusively shares 3 reasons for stunning +420pc session  
 
    Nyrada CEO James Bonner interview with 180 Markets  
 
    Nyrada CEO James Bonner interview with 180 Markets  
 
    Nyrada CEO James Bonner interview with 180 Markets  
 
    Nyrada CEO James Bonner interview with 180 Markets  
 
    Nyrada CEO James Bonner interview with Financial News Network  
 
    Significant Neuroprotection in NYR Preclinical Brain Injury  
 
    Significant Neuroprotection in NYR Preclinical Brain Injury  
 
    Significant Neuroprotection in NYR Preclinical Brain Injury  
 
    Nyrada Half Year Results FY2024  
 
    Nyrada Half Year Results FY2024  
 
    Appendix 4D and Half Year Report to 31 December 2023  
 
    Appendix 4D and Half Year Report to 31 December 2023  
 
    Amended and Restated Certificate of Incorporation and Bylaws  
 
    Amended and Restated Certificate of Incorporation and Bylaws  
 
    Quarterly Activities Report and Appendix 4C  
 
    Quarterly Activities Report and Appendix 4C  
 
    Quarterly Activities Report and Appendix 4C  
 
    Nyrada Receives A$3.54M R&D Tax Incentive Rebate  
 
    Nyrada Receives A$3.54M R&D Tax Incentive Rebate  
 
    Nyrada Receives A$3.54M R&D Tax Incentive Rebate  
 
    Cardiovascular Program  
 
    Lead Drug Development  
 
    Past Shareholder Meetings  
 
    Nyrada Annual General Meeting Results  
 
    Nyrada Annual General Meeting Results  
 
    Nyrada Annual General Meeting Results  
 
    Nyrada AGM 2023 CEO Presentation  
 
    Nyrada AGM 2023 CEO Presentation  
 
    Nyrada AGM 2023 Chair Address  
 
    Nyrada AGM 2023 Chair Address  
 
    2023 AGM Chair Letter to Shareholders  
 
    2023 AGM Chair Letter to Shareholders  
 
    2023 AGM Chair Letter to Shareholders  
 
    Proxy Form  
 
    Proxy Form  
 
    2023 AGM Notice of Meeting and Proxy  
 
    2023 AGM Notice of Meeting and Proxy  
 
    2023 AGM Notice of Meeting and Proxy  
 
    2023 AGM Letter to Shareholders and Proxy  
 
    2023 AGM Letter to Shareholders and Proxy  
 
    Quarterly Activities Report and Appendix 4C  
 
    Quarterly Activities Report and Appendix 4C  
 
    Quarterly Activities Report and Appendix 4C  
 
    Privacy Policy  
 
    Nyrada Full Year Results FY2023  
 
    Nyrada Full Year Results FY2023  
 
    Nyrada Full Year Results FY2023  
 
    Annual Report for year ended 30 June 2023  
 
    Annual Report for year ended 30 June 2023  
 
    Annual Report for year ended 30 June 2023  
 
    Annual Report for year ended 30 June 2023  
 
    Preliminary Final Report  
 
    Preliminary Final Report  
 
    Preliminary Final Report  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4G and Corporate Governance Statement  
 
    Quarterly Activities Report and Appendix 4C  
 
    Quarterly Activities Report and Appendix 4C  
 
    Quarterly Activities Report and Appendix 4C  
 
    Nyrada Review of Operating Costs  
 
    Nyrada Review of Operating Costs  
 
    Nyrada Review of Operating Costs  
 
    TRPC Channels Activated by G Protein‑Coupled Receptors Drive Ca2+ Dysregulation Leading to Secondary Brain Injury in the Mouse Model  
 
    Cholesterol-Lowering Program Update  
 
    Cholesterol-Lowering Program Update  
 
    Cholesterol-Lowering Program Update  
 
    Brain Injury Program Preclinical Development Update  
 
    Brain Injury Program Preclinical Development Update  
 
    Brain Injury Program Preclinical Development Update  
 
    Cholesterol-Lowering Program Preclinical Studies Completed  
 
    Cholesterol-Lowering Program Preclinical Studies Completed  
 
    Cholesterol-Lowering Program Preclinical Studies Completed  
 
    Quarterly Activities Report and Appendix 4C  
 
    Quarterly Activities Report and Appendix 4C  
 
    Quarterly Activities Report and Appendix 4C  
 
    Quarterly Activities Report and Appendix 4C  
 
    Cholesterol-Lowering Program Preclinical Development Update  
 
    Cholesterol-Lowering Program Preclinical Development Update  
 
    Drug Development Pathway  
 
    Drug Development Pathway  
 
    Nyrada Half Year Results FY2023  
 
    Nyrada Half Year Results FY2023  
 
    Appendix 4D and Half Year Report to 31 December 2022  
 
    Appendix 4D and Half Year Report to 31 December 2022  
 
    Appendix 4D and Half Year Report to 31 December 2022  
 
    Technical Glossary  
 
    Brain Injury Program  
 
    Quarterly Activities Report and Appendix 4C  
 
    Quarterly Activities Report and Appendix 4C  
 
    Quarterly Activities Report and Appendix 4C  
 
    Collaboration with Walter Reed and UNSW Extended to 2025  
 
    Collaboration with Walter Reed and UNSW Extended to 2025  
 
    Notification of cessation of securities - NYR  
 
    Notification of cessation of securities - NYR  
 
    Brain Injury Program Update  
 
    Brain Injury Program Update  
 
    James Bonnar (CEO) speaks to Tony Locantro (Alto Capital) about Nyrada’s Phase I Cholesterol Lowering Study  
 
    Results of Meeting  
 
    Results of Meeting  
 
    Results of Meeting  
 
    AGM Presentation by James Bonnar CEO  
 
    AGM Presentation by James Bonnar CEO  
 
    AGM Presentation by James Bonnar CEO  
 
    Nyrada AGM 2022 Chairmans Address  
 
    Nyrada AGM 2022 Chairmans Address  
 
    Nyrada AGM 2022 Chairmans Address  
 
    Nyrada Receives A$1.2M R&D Tax Incentive Rebate  
 
    Nyrada Receives A$1.2M R&D Tax Incentive Rebate  
 
    CEO Remuneration Update  
 
    CEO Remuneration Update  
 
    Quarterly Activities Report and Appendix 4C  
 
    Quarterly Activities Report and Appendix 4C  
 
    Proxy Form  
 
    2022 AGM Letter to Shareholders and Proxy  
 
    2022 AGM Letter to Shareholders and Proxy  
 
    2022 AGM Notice of Meeting and Proxy  
 
    2022 AGM Notice of Meeting and Proxy  
 
    A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo  
 
    Efficacy Study Published in Journal of Lipid Research  
 
    Efficacy Study Published in Journal of Lipid Research  
 
    Nyrada (ASX:NYR) CEO, James Bonnar presentation to ShareCafe’s Hidden Gems Webinar, September 2022  
 
    Presentation to ShareCafe Hidden Gems Webinar  
 
    Presentation to ShareCafe Hidden Gems Webinar  
 
    Presentation to ShareCafe Hidden Gems Webinar  
 
    Presentation to E&P Small Caps Health Care Conference  
 
    Presentation to E&P Small Caps Health Care Conference  
 
    Presentation to E&P Small Caps Health Care Conference  
 
    Nyrada Reports Full Year FY2022 Results  
 
    Nyrada Reports Full Year FY2022 Results  
 
    Annual Report to June 30 2022  
 
    Annual Report to June 30 2022  
 
    Annual Report to June 30 2022  
 
    Preliminary Final Report  
 
    Preliminary Final Report  
 
    Preliminary Final Report  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4G and Corporate Governance Statement  
 
    Nyrada Board Changes  
 
    Nyrada Board Changes  
 
    Initial Director's Interest Notice - GM  
 
    Initial Director's Interest Notice - GM  
 
    Final Director's Interest Notice - PM  
 
    Final Director's Interest Notice - PM  
 
    Quarterly Activities Report and Appendix 4C  
 
    Quarterly Activities Report and Appendix 4C  
 
    Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis  
 
    Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis  
 
    Cholesterol-Lowering Program Update  
 
    Cholesterol-Lowering Program Update  
 
    Corporate Presentation  
 
    Corporate Presentation  
 
    Corporate Presentation  
 
    Brain Injury Program Target Unveiled and Phase I Update  
 
    Brain Injury Program Target Unveiled and Phase I Update  
 
    European Patent to be Granted for Cholesterol-Lowering Drug  
 
    European Patent to be Granted for Cholesterol-Lowering Drug  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Investor Roadshow Presentation  
 
    Investor Roadshow Presentation  
 
    New Drug Offers Potential Oral Treatment for Concussion  
 
    New Drug Offers Potential Oral Treatment for Concussion  
 
    Presentation to Meet the CEO Life Sciences Edition  
 
    Presentation to Meet the CEO Life Sciences Edition  
 
    Presentation to Meet the CEO Life Sciences Edition  
 
    Nyrada Half Year Results FY2022  
 
    Nyrada Half Year Results FY2022  
 
    Appendix 4D and Half Year Report to 31 December 2021  
 
    Appendix 4D and Half Year Report to 31 December 2021  
 
    Investor Welcome  
 
    Share Price Information  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Application for quotation of securities - NYR  
 
    Application for quotation of securities - NYR  
 
    Change of Director's Interest Notice - ID  
 
    Change of Director's Interest Notice - ID  
 
    Change of Director's Interest Notice - MF  
 
    Change of Director's Interest Notice - MF  
 
    Change of Director's Interest Notice - RW  
 
    Change of Director's Interest Notice - RW  
 
    Change of Director's Interest Notice - JM  
 
    Change of Director's Interest Notice - JM  
 
    Change of Director's Interest Notice - CC  
 
    Change of Director's Interest Notice - CC  
 
    Change of Director's Interest Notice - PM  
 
    Change of Director's Interest Notice - PM  
 
    Nyrada Receives A$1.3M R&D Tax Incentive Rebate  
 
    Nyrada Receives A$1.3M R&D Tax Incentive Rebate  
 
    Brain Injury Program Update and Pathway to Phase I  
 
    Brain Injury Program Update and Pathway to Phase I  
 
    Cholesterol-Lowering Program Pathway to Phase I  
 
    Cholesterol-Lowering Program Pathway to Phase I  
 
    Release of Securities from Escrow  
 
    Release of Securities from Escrow  
 
    Nyrada Annual General Meeting Results  
 
    Nyrada Annual General Meeting Results  
 
    Annual General Meeting Presentation  
 
    Annual General Meeting Presentation  
 
    Nyrada AGM 2021 Chairman's Address  
 
    Nyrada AGM 2021 Chairman's Address  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    2021 AGM Notice of Meeting and Proxy  
 
    2021 AGM Notice of Meeting and Proxy  
 
    2021 AGM Letter to Shareholders and Proxy  
 
    2021 AGM Letter to Shareholders and Proxy  
 
    Nyrada (ASX:NYR) CEO, James Bonnar presents at the ASX Small and Mid-Cap Conference  
 
    Nyrada (ASX:NYR) CEO, James Bonnar interview with Andrew Scott (Proactive Investors) at the ASX Small and Mid-Cap Conference, September 2021  
 
    Nyrada (ASX:NYR) CEO, James Bonnar presents at the ASX Small and Mid-Cap Conference  
 
    Nyrada (NYR: ASX) CEO, James Bonnar interview with Andrew Scott (Proactive Investors) at the ASX Small and Mid-Cap Conference, September 2021  
 
    Presentation to ASX Small and Mid-Cap Conference  
 
    Presentation to ASX Small and Mid-Cap Conference  
 
    RaaS Report - Nyrada  

Report prepared as part of ASX Small and Mid-Cap Conference - 14 September 2021.

 
    Contact Us  
 
    Anti-Bribery and Corruption Policy  
 
    Nyrada Inc. Whistleblower Policy  
 
    SECURITIES TRADING POLICY  
 
    REMUNERATION & NOMINATION COMMITTEE CHARTER  
 
    DIVERSITY POLICY  
 
    COMMUNICATION AND DISCLOSURE POLICY  
 
    CODE OF CONDUCT  
 
    BOARD CHARTER  
 
    AUDIT & RISK COMMITTEE CHARTER  
 
    NYRADA INC (ASX:NYR) – BOARD SKILLS MATRIX SUMMARY  
 
    Nyrada Statement of Values  
 
    Updated Share Trading Policy  
 
    Updated Share Trading Policy  
 
    Nyrada Reports Full Year FY2021 Results  
 
    Nyrada Reports Full Year FY2021 Results  
 
    Annual Report to 30 June 2021  
 
    Annual Report to 30 June 2021  
 
    Annual Report to 30 June 2021  
 
    Preliminary Final Report  
 
    Preliminary Final Report  
 
    Preliminary Final Report  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4G and Corporate Governance Statement  
 
    NYX-PCSK9i In Vivo Study Exploratory Analysis Results  
 
    NYX-PCSK9i In Vivo Study Exploratory Analysis Results  
 
    Nyrada Announces US Patent Grant for PCSK9 Inhibitor  
 
    Nyrada Announces US Patent Grant for PCSK9 Inhibitor  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Nyrada (ASX:NYR) CEO, James Bonnar interview with FNN, June 2021  
 
    Nyrada (ASX:NYR) interview with Finance News Network, June 2021  
 
    Change of Director's Interest Notice - CC  
 
    Change of Director's Interest Notice - CC  
 
    Change of Director's Interest Notice - ID  
 
    Change of Director's Interest Notice - ID  
 
    Change of Director's Interest Notice - RW  
 
    Change of Director's Interest Notice - RW  
 
    Change of Director's Interest Notice - MF  
 
    Change of Director's Interest Notice - MF  
 
    Change of Director's Interest Notice - PM  
 
    Change of Director's Interest Notice - PM  
 
    Change of Director's Interest Notice - JM  
 
    Change of Director's Interest Notice - JM  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Cleansing Statement  
 
    Cleansing Statement  
 
    Confirmation of Capital Structure, CDIs on Issue  
 
    Confirmation of Capital Structure, CDIs on Issue  
 
    Notification regarding unquoted securities - NYR  
 
    Notification regarding unquoted securities - NYR  
 
    Application for quotation of securities - NYR  
 
    Application for quotation of securities - NYR  
 
    Application for quotation of securities - NYR  
 
    Application for quotation of securities - NYR  
 
    NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction  
 
    NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction  
 
    Results of Meeting  
 
    Results of Meeting  
 
    Improved Drug Candidate Selected for WRAIR Studies  
 
    Improved Drug Candidate Selected for WRAIR Studies  
 
    Discovery Program  
 
    Notice of Extraordinary General Meeting/Proxy Form  
 
    Notice of Extraordinary General Meeting/Proxy Form  
 
    Nyrada Receives A$1.0M R&D Tax Incentive Rebate  
 
    Nyrada Receives A$1.0M R&D Tax Incentive Rebate  
 
    NYR Announces New Potent Cholesterol-Lowering Candidates  
 
    NYR Announces New Potent Cholesterol-Lowering Candidates  
 
    Change of Registered Office and Principal Place of Business  
 
    Change of Registered Office and Principal Place of Business  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Ceasing to be a substantial holder  
 
    Ceasing to be a substantial holder  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Cleansing Statement  
 
    Cleansing Statement  
 
    Appendix 2A  
 
    Appendix 2A  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Proposed issue of Securities - NYR  
 
    Proposed issue of Securities - NYR  
 
    Nyrada Receives Firm Commitments to Raise A$11 Million  
 
    Nyrada Receives Firm Commitments to Raise A$11 Million  
 
    Nyrada Investor Presentation  
 
    Nyrada Investor Presentation  
 
    Trading Halt  
 
    Trading Halt  
 
    Change of Director's Interest Notice - JM  
 
    Change of Director's Interest Notice - JM  
 
    Nyrada Newsletter February 2021  
 
    Nyrada Newsletter February 2021  
 
    Nyrada Newsletter February 2021  
 
    Nyrada (ASX:NYR) CEO, James Bonnar provides update on lead drug development programs at Finance News Network CEO Showcase, February 2021  
 
    Appendix 3G  
 
    Appendix 3G  
 
    Change of Director's Interest Notice - MF  
 
    Change of Director's Interest Notice - MF  
 
    Nyrada (ASX:NYR) CEO, James Bonnar provides update on lead drug development programs at Finance News Network CEO Showcase, February 2021  
 
    Investor Presentation to Finance News Network CEO Showcase  
 
    Investor Presentation to Finance News Network CEO Showcase  
 
    Nyrada Reports Half Year FY2021 Results  
 
    Nyrada Reports Half Year FY2021 Results  
 
    Appendix 4D and Half Year Accounts  
 
    Appendix 4D and Half Year Accounts  
 
    Appendix 4D and Half Year Accounts  
 
    Appendix 4D and Half Year Accounts  
 
    Lapsing of balance of Unlisted SAB Options  
 
    Lapsing of balance of Unlisted SAB Options  
 
    Cleansing Statement  
 
    Cleansing Statement  
 
    Appendix 2A  
 
    Appendix 2A  
 
    Nyrada (ASX:NYR) discusses collaboration with the Walter Reed Army Institute of Research and UNSW Sydney, February 2021  
 
    Nyrada (ASX:NYR) discusses collaboration with the Walter Reed Army Institute of Research and UNSW Sydney, February 2021  
 
    NYR Secures Collaboration with Walter Reed and UNSW  
 
    NYR Secures Collaboration with Walter Reed and UNSW  
 
    Trading Halt  
 
    Trading Halt  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Nyrada Reports Further Results from Cholesterol Study  
 
    Nyrada Reports Further Results from Cholesterol Study  
 
    Unlisted Scientific Advisory Board Options Expiry 15 Feb 21  
 
    Unlisted Scientific Advisory Board Options Expiry 15 Feb 21  
 
    Change of Director's Interest Notice - ID  
 
    Change of Director's Interest Notice - ID  
 
    Appendix 3G  
 
    Appendix 3G  
 
    Appendix 3G  
 
    Appendix 3G  
 
    Appendix 3G  
 
    Appendix 3G  
 
    Biotech Dispatch: Nyrada reports 'encouraging' early efficacy results from PCSK9i program  

Australian biotech news website, BiotechDispatch said Nyrada had reported "encouraging efficacy results" from an in vivo study involving its NYX-PCSK9i drug candidate.

Read more here

 
    Nyrada (ASX:NYR) discusses progress in cholesterol-lowering drug program, January 2021  
 
    Release of Securities from Escrow  
 
    Release of Securities from Escrow  
 
    Nyrada (ASX:NYR) discusses progress in cholesterol-lowering drug program, January 2021  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    57% Cholesterol Reduction from NYX-PCSK9i In Vivo Study  
 
    57% Cholesterol Reduction from NYX-PCSK9i In Vivo Study  
 
    Appointment of New Auditor  
 
    Appointment of New Auditor  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Cleansing Statement  
 
    Cleansing Statement  
 
    Appendix 2A  
 
    Appendix 2A  
 
    Working at Nyrada Inc  
 
    Change of Director's Interest Notice - JM  
 
    Change of Director's Interest Notice - JM  
 
    Change of Director's Interest Notice - MF  
 
    Change of Director's Interest Notice - MF  
 
    Appendix 2A  
 
    Appendix 2A  
 
    Nyrada Annual General Meeting Results  
 
    Nyrada Annual General Meeting Results  
 
    Presentation to 2020 Annual General Meeting of Shareholders  
 
    Presentation to 2020 Annual General Meeting of Shareholders  
 
    Presentation to 2020 Annual General Meeting of Shareholders  
 
    Nyrada AGM 2020 Chairmans Address  
 
    Nyrada AGM 2020 Chairmans Address  
 
    Pitt Street Research Interview with Nyrada CEO, Mr James Bonnar  
 
    Nyrada Inc - Hidden Gems Webinar Presentation  
 
    Pitt Street Research Interview with Nyrada CEO, Mr James Bonnar  

 
    Release of Securities from Escrow  
 
    Release of Securities from Escrow  
 
    Unlisted Convertible Note Options Expiring 30 November 2020  
 
    Unlisted Convertible Note Options Expiring 30 November 2020  
 
    Pitt Street Research Initiation Report  
 
    2020 Annual General Meeting Reminder  
 
    2020 Annual General Meeting Reminder  
 
    Letter to Shareholders and Proxy Form in relation to AGM  
 
    Letter to Shareholders and Proxy Form in relation to AGM  
 
    Notice of Annual General Meeting and Proxy Form  
 
    Notice of Annual General Meeting and Proxy Form  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Nyrada Quarterly Activities Report & Appendix 4C  
 
    Appendix 4C - September 2020 Quarterly Report  
 
    Nyrada Newsletter September 2020  
 
    Nyrada Newsletter September 2020  
 
    Nyrada Newsletter September 2020  
 
    Notification of Date of 2020 Annual General Meeting  
 
    Notification of Date of 2020 Annual General Meeting  
 
    Change of Director's Interest Notice - JM  
 
    Change of Director's Interest Notice - JM  
 
    Nyrada Inc - Hidden Gems Webinar Presentation  

 
    Corporate Presentation for ShareCafe Hidden Gems Webinar  
 
    Corporate Presentation for ShareCafe Hidden Gems Webinar  
 
    Nyrada Investor Webinar  
 
    Nyrada Investor Webinar  
 
    Nyrada 2020 Appendix 4G and Corporate Governance Statement  
 
    Initial Director's Interest Notice - ID  
 
    Initial Director's Interest Notice - ID  
 
    Final Director's Interest Notice - GK  
 
    Final Director's Interest Notice - GK  
 
    Annual Report to 30 June 2020  
 
    Annual Report to 30 June 2020  
 
    Annual Report to 30 June 2020  
 
    Appendix 4G and Corporate Governance Statement  
 
    Appendix 4G and Corporate Governance Statement  
 
    FY 2020 Appendix 4E Preliminary Financial Report  
 
    FY 2020 Appendix 4E and Preliminary Financial Report  
 
    FY 2020 Appendix 4E Preliminary Financial Report  
 
    Nyrada Board Changes  
 
    Nyrada Board Changes  
 
    Nyrada July/August 2020 webinar recording: New Therapies for Cardiovascular and Neurological Diseases, August 2020  
 
    Nyrada July/August 2020 webinar recording: New Therapies for Cardiovascular and Neurological Diseases, August 2020  

 
    Nyrada Global Webcast Invitation  
 
    Nyrada Global Webcast Invitation  
 
    Nyrada A$1.0M R&D Tax Rebate & Use of Funds Annexure  
 
    Nyrada A$1.0M R&D Tax Rebate & Use of Funds Annexure  
 
    Nyrada Roadshow Corporate Presentation  
 
    Nyrada Roadshow Corporate Presentation July/August 2020  
 
    Nyrada Roadshow Corporate Presentation  
 
    Appendix 4C - June 2020 Quarterly Report  
 
    Appendix 4C - June 2020 Quarterly Report  
 
    Appendix 4C - June 2020 quarterly report  
 
    Nyrada Brain Injury Drug Pharmacokinetic Study Results  
 
    Nyrada Brain Injury Drug Pharmacokinetic Study Results  
 
    Nyrada Brain Injury Data Published by Premier US Military Health Conference  
 
    Nyrada Abstract_MHSRS 2020 conference  
 
    Nyrada Brain Injury Data Published by Premier US Military Health Conference  
 
    Nyrada Brain Injury Data Published by Premier US Military Health Conference  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Nyrada Cholesterol-Lowering Drug Study Results  
 
    Nyrada Cholesterol-Lowering Drug Study Results  
 
    Nyrada presents at the Reach Markets "Meet the CEO's" virtual event June 24, 2020  
 
    Nyrada Newsletter June 2020  
 
    Nyrada Newsletter June 2020  
 
    Nyrada Newsletter June 2020  
 
    Nyrada presents at the Reach Markets "Meet the CEO's" virtual event June 24, 2020  

 
    Corporate Presentation for the Reach Markets Virtual Event  
 
    Corporate Presentation for the Reach Markets Virtual Event  
 
    Milestone Achieved in the Nyrada Brain Injury Program  
 
    Milestone Achieved in the Nyrada Brain Injury Program  
 
    Nyrada Virtual Investor Event 30 April 2020  
 
    Nyrada Virtual Investor Event 30 April 2020  
 
    Nyrada Preclinical Program & Corporate Update Presentation  
 
    Nyrada Preclinical Program & Corporate Update Presentation  
 
    Nyrada Preclinical Program & Corporate Update Presentation  
 
    Change of Director's Interest Notice - JM  
 
    Change of Director's Interest Notice - JM  
 
    Appointment of New Chief Financial Officer  
 
    Appointment of New Chief Financial Officer  
 
    Preclinical Program & Corporate Update Global Webinar  
 
    Preclinical Program & Corporate Update Global Webinar  
 
    Appendix 4C - March 2020 Quarterly Report  
 
    Appendix 4C - March 2020 quarterly  
 
    Appendix 4C - March 2020 quarterly  
 
    Nyrada Newsletter Released  
 
    Nyrada Newsletter Released  
 
    Nyrada Newsletter Released  
 
    Update on Progress in Nyrada Programs  
 
    Update on Progress in Nyrada Programs  
 
    Nyrada Inc. Corporate Presentation February 2020  
 
    Nyrada Inc. Corporate Presentation February 2020  
 
    Nyrada Inc. Corporate Presentation February 2020  
 
    Investor Welcome  
 
    Appendix 4D and Half Yearly Accounts  
 
    Appendix 4D and Half Year Accounts  
 
    Appendix 4D and Half Year Accounts  
 
    Nyrada (ASX: NYR) CEO James Bonnar discusses the company’s commercialisation plans  
 
    Hypercholesterolaemia Drug Candidate Animation  
 
    Significant advance in Nyrada PCSK9i program published  
 
    Significant advance in Nyrada PCSK9i program published  
 
    A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove  
 
    Nyrada Brain Injury Explainer Animation  
 
    Nyrada (ASX:NYR) - new therapies for cardiovascular and neurological disorders  

 
    NYRADA Corporate Governance Statement 2019  
 
    Nyrada Inc - Chairman's letter to shareholders  
 
    Nyrada Inc - Chairman's letter to shareholders  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Nyrada Inc - Corporate Presentation  
 
    Nyrada Inc - Corporate Presentation  
 
    Nyrada Inc - Corporate Presentation  
 
    NOX: Listing of Nyrada Inc. spin-off on ASX  
 
    NOX: Listing of Nyrada Inc. spin-off on ASX  
 
    NYR Commences Trading on the ASX  
 
    NYR Commences Trading on the ASX  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Initial Director's Interest Notice  
 
    Success  
 
    Autoimmune  
 
    Regulation S-Foreign Ownership Restrictions  
 
    Regulation S-Foreign Ownership Restrictions  
 
    Regulation S-Foreign Ownership Restrictions  
 
    Confirmation and Waiver under ASX Listing Rules  
 
    Pre-Quotation Disclosure  
 
    Updated Pro-forma - Financial Position and Commitments  
 
    Securities Trading Policy  
 
    Capital Structure and Restricted Securities  
 
    Financial Statements Year End 30 June 2019  
 
    Financial Statements Year End 30 June 2018  
 
    Corporate Governance Statement  
 
    Equity Incentive Plan  
 
    Amended and Restated Certificate of Incorporation and Bylaws  
 
    Supplementary Prospectus  
 
    Prospectus  
 
    Appendix 1A, Information Form and Checklist, Annexure 3  
 
    Distribution Schedule  
 
    Top 20 Securityholders  
 
    ASX Market Release - Admission and Quotation  
 
    Inflammation/Pain  
 
    Overseas Investors  
 
    Whistleblower Policy  
 
    Code of Conduct  
 
    Securities Trading Policy  
 
    Diversity Policy  
 
    Risk Management Policy  
 
    Communication and Disclosure Policy  
 
    Audit and Risk Committee Charter  
 
    Remuneration and Nomination Committee Charter  
 
    Board Charter  
 
    Nyrada (ASX:NYR) targeting cholesterol-lowering drug candidate  

 
    FNN Interview : Introduction to Nyrada, Inc.  
 
    NOX Releases Initial Newsletter for Nyrada Subsidiary  
 
    Defense TechConnect Summit and Expo. October 8-10 2019, Maryland. USA  
 
    Board Changes Ahead of Corporate Growth  
 
    Thank You  
 
    Share Price Information